{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genes&page=16",
    "query": {
      "condition": "Genes",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 2213,
    "total_pages": 222,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genes&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genes&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T11:31:40.014Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00062036",
      "title": "Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "interleukin-2 gene",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic tumor infiltrating lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 33,
      "start_date": "2003-06",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-26T11:31:40.014Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062036"
    },
    {
      "nct_id": "NCT02317016",
      "title": "Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pharmacokinetic sampling - AZD9291",
          "type": "PROCEDURE"
        },
        {
          "name": "AZD9291 tablet dosing",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Pharmacokinetic sampling - rosuvastatin",
          "type": "PROCEDURE"
        },
        {
          "name": "Pharmacokinetic sampling - AZ5140 and AZ7550",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 44,
      "start_date": "2015-03-10",
      "completion_date": "2018-05-22",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-10-26T11:31:40.014Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02317016"
    },
    {
      "nct_id": "NCT05103358",
      "title": "Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumor",
        "Tumor, Solid",
        "Metastasis",
        "Metastatic Cancer",
        "Cancer",
        "Cancer Metastatic",
        "Tumors",
        "Neoplasms",
        "Neoplasm Metastasis",
        "Solid Tumor",
        "Advanced Solid Tumor",
        "Advanced Cancer",
        "Malignant Solid Tumor",
        "Malignant Solid Neoplasm",
        "Malignant Neoplasm",
        "Malignant Tumor",
        "TSC",
        "TSC1",
        "TSC2",
        "Metastatic Solid Tumor",
        "Metastatic Neoplasm"
      ],
      "interventions": [
        {
          "name": "nab-sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aadi Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2022-03-10",
      "completion_date": "2024-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-26T11:31:40.014Z",
      "location_count": 159,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Prescott Valley",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05103358"
    },
    {
      "nct_id": "NCT06285643",
      "title": "A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "AAV2-GDNF gene therapy",
          "type": "DRUG"
        },
        {
          "name": "control surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "AskBio Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 127,
      "start_date": "2024-06-11",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-26T11:31:40.014Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Irvine, California • Loma Linda, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06285643"
    },
    {
      "nct_id": "NCT00113035",
      "title": "Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pompe Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2005-05",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2015-05-05",
      "last_synced_at": "2026-10-26T11:31:40.014Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00113035"
    },
    {
      "nct_id": "NCT00115752",
      "title": "Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Valdecoxib",
          "type": "DRUG"
        },
        {
          "name": "COX Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Nursing Research (NINR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "7 Years to 35 Years"
      },
      "enrollment_count": 96,
      "start_date": "2005-06-20",
      "completion_date": "2006-10-04",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-26T11:31:40.014Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00115752"
    },
    {
      "nct_id": "NCT04584255",
      "title": "Niraparib + Dostarlimab In BRCA Mutated Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage I Breast Cancer",
        "Stage II Breast Cancer",
        "Stage III Breast Cancer",
        "Breast Cancer",
        "HER2-negative Breast Cancer",
        "Germline BRCA1 Gene Mutation",
        "Germline BRCA2 Gene Mutation",
        "Deleterious PALB2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2021-01-21",
      "completion_date": "2029-07-17",
      "has_results": true,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-26T11:31:40.014Z",
      "location_count": 8,
      "location_summary": "New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04584255"
    },
    {
      "nct_id": "NCT01973543",
      "title": "Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "VY-AADC01",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2013-10",
      "completion_date": "2020-01-24",
      "has_results": false,
      "last_update_posted_date": "2020-03-03",
      "last_synced_at": "2026-10-26T11:31:40.014Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01973543"
    },
    {
      "nct_id": "NCT03375164",
      "title": "A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "delandistrogene moxeparvovec",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Sarepta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "7 Years",
        "sex": "MALE",
        "summary": "3 Months to 7 Years · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2018-01-04",
      "completion_date": "2023-04-25",
      "has_results": true,
      "last_update_posted_date": "2024-11-14",
      "last_synced_at": "2026-10-26T11:31:40.014Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03375164"
    },
    {
      "nct_id": "NCT03042221",
      "title": "Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-Small Cell Carcinoma of Lung, TNM Stage 4",
        "Non-Small Cell Lung Cancer",
        "EGFR Gene Mutation",
        "ALK Gene Mutation",
        "ROSE Cluster 1",
        "BRAF V600E"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 100,
      "start_date": "2016-05-10",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-26T11:31:40.014Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03042221"
    }
  ]
}